StemCell Therapy

Verseons groundbreaking drug discovery platform was featured in Nano Magazines article on whether AI can fundamentally change drug discovery.

Fremont, United States December 21, 2021

Fremont, CA Verseons groundbreaking drug discovery platform was featured in Nano Magazines article on whether AI can fundamentally change drug discovery.

Nano Magazine concluded that although Verseon has built and used its own AI tools for parts of its drug development long before AI was a trendy buzzword, it has avoided the AI hype-fest. With its unique approach that combines physics-based molecular modeling and AI, Verseons platform changes how completely new drugs can be discovered. Whereas other players in AI-driven pharmaceutical development can only find small variations on existing compounds, Verseons platform drives pharmaceutical innovation with rapid, systematic development of multiple previously unexplored, chemically diverse candidates for each of its drug programs, which Nano Magazine called a feat unheard of in the pharmaceutical industry.

Pfizers former SVP of R&D Strategy and Verseon advisor Robert Karr said, Everyone else has merely dabbled in the field of systematic drug discovery. Verseons disruptive platform changes how drugs can be discovered and developed, and the company is poised to make a dramatic impact on modern medicine.

Verseon currently has 14 drug candidates spanning 7 programs in the areas of cardiovascular disease, diabetes, cancer, and liver disease in various stages of development and clinical testing.

Verseons anticoagulant program is currently in Phase 1 clinical trials. This drug (VE-1902) promises to change the standard of care for tens of millions of patients at risk for stroke and heart attack. Ideal treatment for these patients would be long-term combination therapy with antiplatelet and anticoagulant drugs, but this treatment protocol poses significant risk of major bleeding events. Verseons Precision Oral Anticoagulants (PROACs) promise to significantly reduce the risk of major bleeding and would make long-term combination therapy a safe and viable treatment.

UCL Professor of Cardiology John Deanfield remarked: Verseons platelet-sparing anticoagulants with their unique mode of action and low bleeding risk look very promising. Their drugs represent an exciting precision medicine opportunity for the treatment of a large population of cardiovascular disease patients.

About Verseon

To advance global health, Verseon International Corporation (www.verseon.com) has created a better, more scalable process for designing and developing new drugs addressing currently untreatable or poorly treated conditions. The companys drug development platform incorporates fundamental advancements in molecular modeling, directed synthesis, integrated translational research and advanced AI to develop drug compounds that have never before been synthesizedand are virtually impossible to find using conventional methods. Verseon is a clinical-stage company with a growing pipeline that currently includes seven drug programs in the areas of anticoagulation, diabetic retinopathy, hereditary angioedema, oncology, and metabolic disorders.

Contact Info:Name: Walter JonesEmail: Send EmailOrganization: VerseonAddress: 47000 Warm Springs Boulevard, Fremont, CA 94539, United StatesWebsite: https://www.verseon.com

Release ID: 89057403

COMTEX_399338900/2773/2021-12-21T05:54:13

Here is the original post:
Verseon Praised for Disruptive Approach to Physics- and AI-Based Drug Discovery - Digital Journal

This entry was posted on December 22, 2021 at 1:49 am and is filed under Nano medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |